ClinicalTrials.gg
Not yet recruitingNCT07158840AGA TKI NSCLCUpdated Sep 8, 2025

AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

A Phase 2 interventional study of AK112 in Non-Small Cell Lung Cancer, sponsored by Akeso. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung — 23 open to participants now, 30 under way, 7 of them phase 3. ivonescimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
19th of 31
60 · median 70
Started
2025
with 5 others
Phase 2
17 of 31
16 open now
Primary completion
2028-09
later than 25 of 29 live
Registered
15th of 31
by date
Lead sponsor
9 of 31
Akeso

Among the 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by planned enrollment, is one of 6 that started in 2025, is one of 17 in phase 2, reaches primary completion later than 25 of the 29 other live ones, and was the 15th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

23 of the 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About ivonescimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed the Form (ICF) voluntarily。
  2. Participants must be aged between 18 and 75 years (inclusive), regardless of gender.
  3. performance status of 0 or 1.
  4. With a of ≥3 months.
  5. or cytologically confirmed locally advanced (stage IIIB/IIIC) or (stage IV) non-squamous NSCLC.
  6. Prior to enrollment, participants must have at least one actionable genomic alteration (AGA) confirmed by tumor histology, cytology, or blood-based testing, including: EGFR, ALK, ROS1, NTRK, RET, BRAF and MET. Participants must provide a prior AGA test report; otherwise, AGA testing must be performed at the study site or at a site-designated laboratory before enrollment.
  7. Previous treatment failure with an AGA-targeted TKI.
  8. At least one measurable extracranial lesion as defined by v1.1.
  9. Adequate organ function confirmed.

Exclusion criteria

Exclusion Criteria:

  1. Histological or cytological pathology confirming the presence of a small-cell carcinoma component or a predominant squamous cell carcinoma component.
  2. AGA test report showing the presence of a common EGFR sensitizing mutation.
  3. Prior receipt of immunotherapy.
  4. Prior receipt of any systemic anti-tumor therapy for advanced-stage (IIIB-IV) NSCLC other than AGA-targeted TKIs.
  5. Concurrent participation in another clinical study, unless it is a non-interventional study or the follow-up phase of an interventional study.
  6. Receipt of AGA-targeted TKI therapy within 2 weeks prior to the first dose; receipt of non-specific immunomodulatory therapy within 2 weeks prior to the first dose.
  7. Imaging during the screening period shows tumor encasement of major blood vessels or significant necrosis/cavitation, and the investigator determines that study participation would pose a bleeding risk.
  8. Imaging during the screening period shows tumor invasion of surrounding vital organs or blood vessels.
  9. Central nervous system : participants assessed by the investigator as not requiring local treatment may be eligible; are not eligible.
  10. History of other than NSCLC within 3 years prior to the first dose; participants with other malignancies that have been cured by local treatment are allowed.
  11. Active disease requiring systemic therapy within 2 years prior to the first dose.
  12. History of major medical conditions within 1 year prior to the first dose.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Drug: AK112

Interventions

  • DrugAK112

    AK112 Monotherapy

06

What researchers measure

Primary outcomes

  1. Overall response (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator

    Proportion of subjects who have a complete or partial response as assessed according to RECIST v1.1.

    Time frame: up to 2 years

Secondary outcomes

  1. Overall survival (OS)

    From date of enrollment until the date of death from any cause

    Time frame: up to 2 years

  2. Progression-free survival (PFS)

    From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first

    Time frame: up to 2 years

  3. Duration of response (DoR)

    Duration of response (DoR), which is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: up to 2 years

  4. Disease control rate (DCR)

    Disease control rate (DCR), which is defined as the proportion of subjects with complete response (CR), partial response (PR), or stable disease (SD), based on RECIST v1.1

    Time frame: up to 2 years

  5. Time to response (TTR)

    TTR is defined as the time to response base on RECIST v1.1

    Time frame: up to 2 years

  6. Percentage of participants with adverse event (AE)

    The percentage of participants experiencing an adverse event (AE) and the severity of AEs will be assessed

    Time frame: From the subject signs the Informed Consent Form to 30 days (AE) and 90 days (Serious AE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first,up to 2 years

  7. Observed concentrations of AK112

    The endpoints for assessment of Pharmacokinetics (PK) of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration

    Time frame: From date of enrollment until the end of treatment, assessed up to 2 years

  8. Number of participants who develop detectable anti-drug antibodies (ADAs)

    The immunogenicity of AK112 will be assessed by summarizing the number of participants who develop detectable antidrug antibodies (ADAs)

    Time frame: From first dose of AK112 through 90 days after last dose of AK112,up to 2 years

  9. Number of participants with programmed cell death ligand 1 (PD-L1) expression positive who achieve CR/PR

    Time frame: From date of enrollment until the end of treatment, assessed up to 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Sep 2028, 36 months later.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 36 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Sep 8, 2025
StartEst.
Sep 5, 2025
Primary completionEst.
Sep 2028
CompletionEst.
Jun 2029
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07158840
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Sep 5, 2025 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Sep 8, 2025

Study contacts

Ting Liu
Contact
clinicaltrials@akesobio.com
0760-89873925

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion